PYC Physiomics Plc

LSE · GB · Healthcare · Biotechnology · physiomics.co.uk

0.5250GBp0.00%Mkt Cap: 2.59M $P/E: —Today

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Swit…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap2.59M USD

Enterprise Value1.45M USD

Revenue (TTM)1.10M USD

Gross Profit-557.69K USD

Net Income (TTM)-451.36K USD

Revenue/Share0.0030 GBp

Last Price0.5250 GBp

Fiscal Year EndJun 2025

MR QuarterDec 2025

Employees10

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.02

PEG—

EV/EBITDA-2.55

EV/Revenue1.32

P/S2.36

P/B5.25

EPS (TTM)0.00

EPS (Forward)-0.34

52W Range

0.253050% of range0.8000

52W High0.8000 GBp

52W Low0.2530 GBp

Profitability

Gross Margin-50.89%

Oper. Margin-61.93%

EBITDA Margin-51.91%

Profit Margin-52.97%

ROE-59.99%

ROA-46.55%

Growth

Revenue Growth49.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-593.63K USD

CapEx (TTM)4.28K USD

FCF Margin-31.45%

FCF Yield-13.33%

Net Debt-279.35K USD

Net Debt/EBITDA0.49

Balance Sheet

Debt/Equity—

Current Ratio3.30

Quick Ratio3.30

Book Value/Sh0.0010 GBp

Cash/Share0.0010 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:100

Split DateDec 19, 2016

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.453.21M

Float203.54M

Insiders25.73%

Institutions2.30%

Technical

SMA 500.4995 (+5.1%)

SMA 2000.4843 (+8.4%)

Beta1.05

S&P 52W Chg14.58%

Avg Vol (30d)3.70M

Avg Vol (10d)4.94M

Technical Indicators

RSI (14)54.2

MACD0.0056

MACD Signal0.0062

MACD Hist.-0.0006

BB Upper0.5569 GBp

BB Middle0.5232 GBp

BB Lower0.4896 GBp

BB Width12.84%

ATR (14)0.0437 GBp

Vol Ratio (20d)0.04x